This version of Orrick’s life sciences publication sequence opinions the important thing drivers of enterprise funding within the life sciences business, which is continuing at a report tempo to this point in 2021. Key findings embody:
Funding continues at a report tempo. By midyear 2021, $25.3 billion of enterprise capital has been invested into US-based life sciences firms—a sum already increased than eight different years’ annual tallies since 2010.
The rising inflow of capital has boosted deal metrics throughout all financing sequence.
favorable backdrop for buyers, with preliminary public providing (IPO) sizes specifically surging to new data—$36.4 billion in combination exit worth by midyear.
In any heady setting, there can be rightful requires warning and rigor in funding processes. Nonetheless, the speed of technical innovation and dimension of market alternatives can even justify vital funding.
Please see full Publication beneath for extra data.